Literature DB >> 1331098

Structural constraints within a trimeric transcriptional regulatory region. Constitutive and interferon-gamma-inducible expression of the HLA-DRA gene.

B J Vilen1, J F Penta, J P Ting.   

Abstract

Constitutive and inducible transcription of the major histocompatibility class II HLA-DRA gene involves the upstream S element and the conserved X and Y elements. In this report we have addressed the roles of spatial constraints and stereospecific alignment between the upstream S and X elements, and the X and Y elements, in both constitutive and interferon-gamma (gamma-IFN)-induced expression. Analysis of the constitutive expression in B cell lines (B-LCL) has previously shown that the X and Y elements must be stereoaligned. Further study reveals that any spacing changes between S and X, regardless of the helical alignment of these two elements, is not tolerated. These same restraints are involved in an inducible system, because the response to gamma-IFN treatment requires both stereo alignment between the X and Y elements and precise spacing between the S and X elements. Neither constitutive nor inducible expression can be restored by correcting the distance and spacing between only the S and Y elements with misalignment of X. These results reveal a common pathway for constitutive and inducible expression that may require either direct or indirect protein complex formation among proteins bound to three highly conserved regulatory elements. We have also evaluated the role of the A/T-rich sequence located immediately 5' of the Y element and show that it exerts little effect on constitutive and gamma-IFN induced DRA expression.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1331098

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

1.  CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex.

Authors:  K Masternak; A Muhlethaler-Mottet; J Villard; M Zufferey; V Steimle; W Reith
Journal:  Genes Dev       Date:  2000-05-01       Impact factor: 11.361

Review 2.  Class II transactivator: mastering the art of major histocompatibility complex expression.

Authors:  J A Harton; J P Ting
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

Review 3.  Impaired regulation of HLA-DR expression in human immunodeficiency virus-infected monocytes.

Authors:  Ling Shao; Kirk Sperber
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

Review 4.  Novel mechanisms of class II major histocompatibility complex gene regulation.

Authors:  Michael Radosevich; Santa Jeremy Ono
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

5.  Complex architecture of major histocompatibility complex class II promoters: reiterated motifs and conserved protein-protein interactions.

Authors:  N Jabrane-Ferrat; J D Fontes; J M Boss; B M Peterlin
Journal:  Mol Cell Biol       Date:  1996-09       Impact factor: 4.272

6.  Function of major histocompatibility complex class II promoters requires cooperative binding between factors RFX and NF-Y.

Authors:  W Reith; C A Siegrist; B Durand; E Barras; B Mach
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-18       Impact factor: 11.205

Review 7.  Current concepts in DRA gene regulation.

Authors:  J P Ting
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

8.  Repression of major histocompatibility complex I-A beta gene expression by dbpA and dbpB (mYB-1) proteins.

Authors:  J Lloberas; R A Maki; A Celada
Journal:  Mol Cell Biol       Date:  1995-09       Impact factor: 4.272

9.  Locus- and allele-specific DNA-protein interactions in the HLA-DQB1 X box.

Authors:  T L Sukiennicki; L M Shewey; G T Nepom
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

10.  Major histocompatibility complex class II transcriptional platform: assembly of nuclear factor Y and regulatory factor X (RFX) on DNA requires RFX5 dimers.

Authors:  Nabila Jabrane-Ferrat; Nada Nekrep; Giovanna Tosi; Laura J Esserman; B Matija Peterlin
Journal:  Mol Cell Biol       Date:  2002-08       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.